Growth Metrics

Vanda Pharmaceuticals (VNDA) Gains from Sales and Divestitures (2016 - 2018)

Historic Gains from Sales and Divestitures for Vanda Pharmaceuticals (VNDA) over the last 8 years, with Q1 2018 value amounting to $475367.0.

  • Vanda Pharmaceuticals' Gains from Sales and Divestitures rose 3679.47% to $475367.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $475367.0, marking a year-over-year increase of 3679.47%. This contributed to the annual value of $362313.0 for FY2017, which is 2594.92% up from last year.
  • Vanda Pharmaceuticals' Gains from Sales and Divestitures amounted to $475367.0 in Q1 2018, which was up 3679.47% from $362313.0 recorded in Q4 2017.
  • Vanda Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $475367.0 for Q1 2018, and its period low was $209562.0 during Q1 2014.
  • Over the past 5 years, Vanda Pharmaceuticals' median Gains from Sales and Divestitures value was $287666.0 (recorded in 2016), while the average stood at $282623.5.
  • Over the last 5 years, Vanda Pharmaceuticals' Gains from Sales and Divestitures had its largest YoY gain of 3747.54% in 2014, and its largest YoY loss of 416.33% in 2014.
  • Vanda Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $209562.0 in 2014, then increased by 10.27% to $231093.0 in 2015, then grew by 24.48% to $287666.0 in 2016, then rose by 25.95% to $362313.0 in 2017, then soared by 31.2% to $475367.0 in 2018.
  • Its Gains from Sales and Divestitures stands at $475367.0 for Q1 2018, versus $362313.0 for Q4 2017 and $356127.0 for Q3 2017.